Transcriptome Signature of Immune Cells Post Reovirus Treatment in KRAS Mutated Colorectal Cancer

References

• RoundtreeIA, EvansME, PanT, et al. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169(7):1187–1200. doi:10.1016/j.cell.2017.05.04528622506
   PubMed Web of Science ®Google Scholar
• LaffleurB, BasuU. Biology of RNA surveillance in development and disease. Trends Cell Biol. 2019;29(5):428–445. doi:10.1016/j.tcb.2019.01.00430755352
   PubMed Web of Science ®Google Scholar
• CoelhoSM, PetersAF, CharrierB, et al. Complex life cycles of multicellular eukaryotes: new approaches based on the use of model organisms. Gene. 2007;406(1–2):152–170. doi:10.1016/j.gene.2007.07.02517870254
   PubMed Web of Science ®Google Scholar
• NagalakshmiU, WangZ, WaernK, et al. The transcriptional landscape of the yeast genome defined by RNA sequencing. Science. 2008;320(5881):1344–1349. doi:10.1126/science.115844118451266
   PubMed Web of Science ®Google Scholar
• BainbridgeMN, WarrenRL, HirstM, et al. Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach. BMC Genomics. 2006;7(1):246. doi:10.1186/1471-2164-7-24617010196
   PubMed Web of Science ®Google Scholar
• Surget-GrobaY, Montoya-BurgosJI. Optimization of de novo transcriptome assembly from next-generation sequencing data. Genome Res. 2010;20(10):1432–1440. doi:10.1101/gr.103846.10920693479
   PubMed Web of Science ®Google Scholar
• DobinA, DavisCA, SchlesingerF, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21. doi:10.1093/bioinformatics/bts63523104886
   PubMed Web of Science ®Google Scholar
• GoelS, OceanAJ, ParakramaRY, et al. Elucidation of pelareorep pharmacodynamics in a phase I trial in patients with KRAS-mutated colorectal cancer. Mol Cancer Ther. 2020;19(5):1148–1156.32156785
   PubMed Web of Science ®Google Scholar
• MaitraR, GhalibMH, GoelS. Reovirus: a targeted therapeutic–progress and potential. Mol Cancer Res. 2012;10(12):1514–1525. doi:10.1158/1541-7786.MCR-12-015723038811
   PubMed Web of Science ®Google Scholar
• MaitraR, SeetharamR, TesfaL, et al. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan. Oncotarget. 2014;5(9):2807–2819. doi:10.18632/oncotarget.192124798549
   PubMedGoogle Scholar
• NormanKL, CoffeyMC, HirasawaK, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther. 2002;13(5):641–652. doi:10.1089/1043034025283723311916487
   PubMed Web of Science ®Google Scholar
• StrongJE, CoffeyMC, TangD, et al. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998;17(12):3351–3362. doi:10.1093/emboj/17.12.33519628872
   PubMed Web of Science ®Google Scholar
• LalR, HarrisD, Postel-VinayS, et al. Reovirus: rationale and clinical trial update. Curr Opin Mol Ther. 2009;11(5):532–539.19806501
   PubMedGoogle Scholar
• GollamudiR, GhalibMH, DesaiKK, et al. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs. 2010;28(5):641–649. doi:10.1007/s10637-009-9279-819572105
   PubMed Web of Science ®Google Scholar
• DuncanMR, StanishSM, CoxDC. Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol. 1978;28(2):444–449. doi:10.1128/jvi.28.2.444-449.1978214572
   PubMed Web of Science ®Google Scholar
• DuursmaAM, AgamiR. Ras interference as cancer therapy. Semin Cancer Biol. 2003;13(4):267–273. doi:10.1016/S1044-579X(03)00040-314563121
   PubMed Web of Science ®Google Scholar
• LivakKJ, SchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.126211846609
   PubMed Web of Science ®Google Scholar
• HaydenMS, WestAP, GhoshS. NF-kappaB and the immune response. Oncogene. 2006;25(51):6758–6780. doi:10.1038/sj.onc.120994317072327
   PubMed Web of Science ®Google Scholar
• ChardinP, CamonisJ, GaleN, et al. Human Sos1: a guanine nucleotide exchange factor for ras that binds to GRB2. Science. 1993;260(5112):1338–1343. doi:10.1126/science.84935798493579
   PubMed Web of Science ®Google Scholar
• ModzelewskaK, ElgortMG, HuangJ, et al. An activating mutation in sos-1 identifies Its Dbl domain as a critical inhibitor of the epidermal growth factor receptor pathway during Caenorhabditis elegans vulval development. Mol Cell Biol. 2007;27(10):3695–3707. doi:10.1128/MCB.01630-0617339331
   PubMed Web of Science ®Google Scholar
• NishidaN, YanoH, NishidaT, et al. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2(3):213–219. doi:10.2147/vhrm.2006.2.3.21317326328
   PubMedGoogle Scholar
• SatohN, YamadaY, KinugasaY, et al. Angiopoietin-1 alters tumor growth by stabilizing blood vessels or by promoting angiogenesis. Cancer Sci. 2008;99(12):2373–2379. doi:10.1111/j.1349-7006.2008.00961.x19018775
   PubMed Web of Science ®Google Scholar
• KingSJ, NowakK, SuryavanshiN, et al. Nesprin-1 and nesprin-2 regulate endothelial cell shape and migration. Cytoskeleton (Hoboken). 2014;71(7):423–434. doi:10.1002/cm.2118224931616
   PubMed Web of Science ®Google Scholar
• YinM, YanJ, WeiS, et al. CASP8 polymorphisms contribute to cancer susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies. Carcinogenesis. 2010;31(5):850–857. doi:10.1093/carcin/bgq04720176653
   PubMed Web of Science ®Google Scholar
• MakiY, BosTJ, DavisC, et al. Avian sarcoma virus 17 carries the jun oncogene. Proc Natl Acad Sci U S A. 1987;84(9):2848–2852. doi:10.1073/pnas.84.9.28483033666
   PubMed Web of Science ®Google Scholar
• WisdomR, JohnsonRS, MooreC. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 1999;18(1):188–197. doi:10.1093/emboj/18.1.1889878062
   PubMed Web of Science ®Google Scholar
• EferlR, RicciR, KennerL, et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell. 2003;112(2):181–192. doi:10.1016/S0092-8674(03)00042-412553907
   PubMed Web of Science ®Google Scholar
• WilsonEM, RotweinP. Control of MyoD function during initiation of muscle differentiation by an autocrine signaling pathway activated by insulin-like growth factor-II. J Biol Chem. 2006;281(40):29962–29971. doi:10.1074/jbc.M60544520016901893
   PubMed Web of Science ®Google Scholar
• LivingstoneC. IGF2 and cancer. Endocr Relat Cancer. 2013;20(6):R321–R339. doi:10.1530/ERC-13-023124080445
   PubMed Web of Science ®Google Scholar
• de YebenesVG, RamiroAR. MicroRNA activity in B lymphocytes. Methods Mol Biol. 2010;667:177–192.20827534
   PubMedGoogle Scholar
• PodshivalovaK, SalomonDR. MicroRNA regulation of T-lymphocyte immunity: modulation of molecular networks responsible for T-cell activation, differentiation, and development. Crit Rev Immunol. 2013;33(5):435–476. doi:10.1615/CritRevImmunol.201300685824099302
   PubMed Web of Science ®Google Scholar
• FerrettiR, SbroggiòM, Di SavinoA, et al. Morgana and melusin: two fairies chaperoning signal transduction. Cell Cycle. 2011;10(21):3678–3683. doi:10.4161/cc.10.21.1820222037254
   PubMed Web of Science ®Google Scholar
• Di SavinoA, PanuzzoC, RoccaS, et al. Morgana acts as an oncosuppressor in chronic myeloid leukemia. Blood. 2015;125(14):2245–2253. doi:10.1182/blood-2014-05-57500125678499
   PubMed Web of Science ®Google Scholar
• FerrettiR, PalumboV, Di SavinoA, et al. Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication and tumorigenesis. Dev Cell. 2010;18(3):486–495. doi:10.1016/j.devcel.2009.12.02020230755
   PubMed Web of Science ®Google Scholar
• WangS, TukachinskyH, RomanoFB, et al. Cooperation of the ER-shaping proteins atlastin, lunapark, and reticulons to generate a tubular membrane network. Elife. 2016;5:e18605.27619977
   PubMed Web of Science ®Google Scholar
• ChristodoulouA, Santarella-MellwigR, SantamaN, et al. Transmembrane protein TMEM170A is a newly discovered regulator of ER and nuclear envelope morphogenesis in human cells. J Cell Sci. 2016;129(8):1552–1565.26906412
   PubMed Web of Science ®Google Scholar
• PathakGP, ShahR, KennedyBE, et al. RTN4 knockdown dysregulates the AKT pathway, destabilizes the cytoskeleton, and enhances paclitaxel-induced cytotoxicity in cancers. Mol Ther. 2018;26(8):2019–2033. doi:10.1016/j.ymthe.2018.05.02630078441
   PubMed Web of Science ®Google Scholar
• TagamiS, EguchiY, KinoshitaM, et al. A novel protein, RTN-XS, interacts with both Bcl-XL and Bcl-2 on endoplasmic reticulum and reduces their anti-apoptotic activity. Oncogene. 2000;19(50):5736–5746. doi:10.1038/sj.onc.120394811126360
   PubMed Web of Science ®Google Scholar
• SchwambB, PickR, FernándezSBM, et al. FAM96A is a novel pro-apoptotic tumor suppressor in gastrointestinal stromal tumors. Int J Cancer. 2015;137(6):1318–1329. doi:10.1002/ijc.2949825716227
   PubMed Web of Science ®Google Scholar
• AmbrosV. The functions of animal microRNAs. Nature. 2004;431(7006):350–355. doi:10.1038/nature0287115372042
   PubMed Web of Science ®Google Scholar
• LiangH, FuZ, JiangX, et al. miR-16 promotes the apoptosis of human cancer cells by targeting FEAT. BMC Cancer. 2015;15(1):448. doi:10.1186/s12885-015-1458-826031775
   PubMed Web of Science ®Google Scholar
• ChenT, XiaoQ, WangX, et al. miR-16 regulates proliferation and invasion of lung cancer cells via the ERK/MAPK signaling pathway by targeted inhibition of MAPK kinase 1 (MEK1). J Int Med Res. 2019;47(10):5194–5204. doi:10.1177/030006051985650531379227
   PubMed Web of Science ®Google Scholar
• SantarpiaL, LippmanSM, El-NaggarAK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):103–119. doi:10.1517/14728222.2011.64580522239440
   PubMed Web of Science ®Google Scholar
• JiaS, LiuZ, ZhangS, et al. Essential roles of PI(3) K-p110betain cell growth, metabolism and tumorigenesis. Nature. 2008;454(7205):776–779. doi:10.1038/nature0709118594509
   PubMed Web of Science ®Google Scholar
• FrancisSH, BuschJL, CorbinJD, et al. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010;62(3):525–563. doi:10.1124/pr.110.00290720716671
   PubMed Web of Science ®Google Scholar
• ParakramaR, FogelE, ChandyC, et al. Immune characterization of metastatic colorectal cancer patients post reovirus administration. BMC Cancer. 2020;20(1):569. doi:10.1186/s12885-020-07038-232552875
   PubMed Web of Science ®Google Scholar
• JiffryJ, ThavornwatanayongT, RaoD, et al. Oncolytic Reovirus (pelareorep) induces autophagy in KRAS-mutated colorectal cancer. Clin Cancer Res. 2021;27(3):865–876. doi:10.1158/1078-0432.CCR-20-238533168658
   PubMed Web of Science ®Google Scholar